In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Spero Therapeutics Inc (SPRO – Research Report), with a price target of $27. The company’s shares opened today at $12.98.
“. Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts for 2019+. Anticipated 2019 events include enrollment in the planned SPR994 pivotal Phase 3 clinical trial and top-line data from 1 clinical trials in 2H19.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.1% and a 41.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Amneal Pharmaceuticals Inc.
Spero Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $28.50.
The company has a one-year high of $19 and a one-year low of $5.52. Currently, Spero Therapeutics Inc has an average volume of 71.22K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206.